Diabetic Neuropathy - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Neuropathy - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Diabetic Neuropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diabetic Neuropathy Overview 10
Therapeutics Development 11
Pipeline Products for Diabetic Neuropathy - Overview 11
Pipeline Products for Diabetic Neuropathy - Comparative Analysis 12
Diabetic Neuropathy - Therapeutics under Development by Companies 13
Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Neuropathy - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Diabetic Neuropathy - Products under Development by Companies 19
Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20
Diabetic Neuropathy - Companies Involved in Therapeutics Development 21
Araim Pharmaceuticals Inc. 21
Bristol-Myers Squibb Company 22
Cebix Incorporated 23
Celgene Corporation 24
Glucox Biotech AB 25
Longevity Biotech, Inc 26
Lpath, Inc. 27
Neuralstem, Inc. 28
NovaLead Pharma Pvt. Ltd. 29
Nuvo Research Inc. 30
Omeros Corporation 31
Pfizer Inc. 32
R-Tech Ueno, Ltd. 33
Reata Pharmaceuticals, Inc. 34
Relief Therapeutics S.A. 35
Sumitomo Dainippon Pharma Co., Ltd. 36
Virobay Inc. 37
ViroMed Co., Ltd. 38
Diabetic Neuropathy - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
atexakin alfa - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
benfotiamine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BNV-222 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CBX-129801 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
cibinetide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CMB-200 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cyndacel-M - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug for Pain - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Flexicaine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ketoprofen - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LBT-3627 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Lpathomab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NLP-198 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NSI-566 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OMS-721 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PDA-002 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PF-05089771 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
pirenzepine hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ranirestat - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
RTA-901 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RTU-1096 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecule to Agonize Kv7.2 for Neuropathic Pain and Diabetic Neuropathy - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules for Diabetic Neuropathy - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
VBY-285 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
VM-202 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Diabetic Neuropathy - Recent Pipeline Updates 89
Diabetic Neuropathy - Dormant Projects 106
Diabetic Neuropathy - Discontinued Products 108
Diabetic Neuropathy - Product Development Milestones 109
Featured News & Press Releases 109
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 109
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 110
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 111
Sep 07, 2011: Cebix To Chair Symposium On C-Peptide And Pathophysiology Of Diabetes At EASD Annual Meeting 111
May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications 112
Mar 18, 2011: ViroMed Enrolls Final Patient for US VM202-DPN Phase I/II Clinical Trial 113
Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 113
Sep 29, 2005: Dainippon and Eisai Signs Licensing Agreement for A Potential New Treatment For Diabetic Neuropathy 113
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables

Number of Products under Development for Diabetic Neuropathy, H2 2015 11
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Investigation by Universities/Institutes, H2 2015 20
Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals Inc., H2 2015 21
Diabetic Neuropathy - Pipeline by Bristol-Myers Squibb Company, H2 2015 22
Diabetic Neuropathy - Pipeline by Cebix Incorporated, H2 2015 23
Diabetic Neuropathy - Pipeline by Celgene Corporation, H2 2015 24
Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H2 2015 25
Diabetic Neuropathy - Pipeline by Longevity Biotech, Inc, H2 2015 26
Diabetic Neuropathy - Pipeline by Lpath, Inc., H2 2015 27
Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H2 2015 28
Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2015 29
Diabetic Neuropathy - Pipeline by Nuvo Research Inc., H2 2015 30
Diabetic Neuropathy - Pipeline by Omeros Corporation, H2 2015 31
Diabetic Neuropathy - Pipeline by Pfizer Inc., H2 2015 32
Diabetic Neuropathy - Pipeline by R-Tech Ueno, Ltd., H2 2015 33
Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H2 2015 34
Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H2 2015 35
Diabetic Neuropathy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 36
Diabetic Neuropathy - Pipeline by Virobay Inc., H2 2015 37
Diabetic Neuropathy - Pipeline by ViroMed Co., Ltd., H2 2015 38
Assessment by Monotherapy Products, H2 2015 39
Number of Products by Stage and Target, H2 2015 41
Number of Products by Stage and Mechanism of Action, H2 2015 43
Number of Products by Stage and Route of Administration, H2 2015 45
Number of Products by Stage and Molecule Type, H2 2015 47
Diabetic Neuropathy Therapeutics - Recent Pipeline Updates, H2 2015 89
Diabetic Neuropathy - Dormant Projects, H2 2015 106
Diabetic Neuropathy - Dormant Projects (Contd..1), H2 2015 107
Diabetic Neuropathy - Discontinued Products, H2 2015 108